Clinical Trials Logo

Clinical Trial Summary

This study is to evaluate the INR levels in patients taking phenprocoumon using the LumiraDx Point of Care INR test and comparing the results to the laboratory reference method , the ACL Elite Pro. Comparison will also be made with the Roche Coaguchek point of care INR test (point of care reference method). Performance will be demonstrated across a subject population of adult males and females in receipt of Phenprocoumon VKA therapy. This population is representative of the indications for use of the CE marked product. Operators will be trained clinical site staff. Venous plasma and capillary whole blood samples will be obtained from each subject in order to assess accuracy of the the LumiraDx Platform when compared to the reference devices (ACL Elite and Coaguchek Pro).


Clinical Trial Description

Vitamin K antagonists (VKA) are a group of substances that reduce blood clotting by reducing the action of vitamin K. They are used in anticoagulant medications in the prevention of thrombosis. The drugs work by depleting the active form of the vitamin by inhibiting Vitamin K epoxide reductase and thus the recycling of inactive vitamin K back to the active reduced form. The most widely prescribed VKAs are Coumarins. This group is composed of several different structurally similar molecules and includes warfarin (Coumadin), acenocoumerol and phenprocoumon.

Within the EU there are country to country differences in preferential VKA prescription (1). In Germany and surrounding countries, Phenprocoumon (marketed as Marcoumar or Marcumar) is the most commonly prescribed. The majority of data supporting the development and validation of the LumriaDx INR test has used samples form patients taking Warfarin. The aim of this study is to evaluate the INR levels in patients taking phenprocoumon using the LumiraDx Point of Care INR test and comparing the results to the laboratory reference method , the ACL Elite Pro. Comparison will also be made with the Roche Coaguchek point of care INR test (point of care reference method).

This study is an observational, cross-sectional study with 100 patients in total. Devices used in this study are CE marked for INR measurement by healthcare professionals. This study will be conducted according to the principles of Good Clinical Practice (ICH GCP E6(R2)), International Conference on Harmonization Guidelines as applicable to devices, applicable geographical regulations and institutional research policies and procedures.

For part 1 of the study (25 patients), one venous whole blood draw will be performed (~9mL) into two anti-coagulated collection tubes (2 x 4.5mL 3.2% trisodium citrate). These tubes will then by processed to plasma by centrifugation, stored in Eppendorf tubes, labelled and frozen at -80ºC . These will then be transferred to the LumriaDx laboratory in Scotland, UK, for subsequent measurement of INR with the reference device IL ACL Elite Pro Coagulation Analyzer (ACL) and with the LumiraDx POC INR test.

For part 2 of the study (75 patients), one finger-stick sample of capillary blood (~10µl/sample) from each subject, will be applied directly to a unique test strip for immediate measurement of INR on the LumiraDx Instrument. One further fingerstick sample is then obtained (~10µl/sample) from a separate finger for immediate measurement of INR on the Coaguchek PRO. Post-testing, samples will be disposed securely. From each patient, one venous whole blood draw will also be performed (~9mL) into two anti-coagulated collection tubes (2 x 4.5mL 3.2% trisodium citrate). These tubes will then by processed to plasma by centrifugation, stored in Eppendorf tubes, labelled and frozen at -80ºC. These will then be transferred to the LumiraDx laboratory in Scotland, UK, for subsequent measurement of INR with the reference device IL ACL Elite Pro Coagulation Analyzer (ACL) and with the LumiraDx POC INR test.

INR results obtained will be used in comparative analyses of performance designed to meet the study objectives. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04074980
Study type Interventional
Source LumiraDx UK Limited
Contact
Status Completed
Phase N/A
Start date May 9, 2019
Completion date September 15, 2019

See also
  Status Clinical Trial Phase
Completed NCT04517461 - Coagulation and Vitamin K in Head and Neck Microvascular Free Flap Surgery
Terminated NCT03296033 - Residual Anti-Xa Activity After Last Treatment Dose of Enoxaparin Phase 4
Recruiting NCT05123326 - Global Coagulation Assessment in Portal Vein Thrombosis and Budd-Chiari Syndrome
Completed NCT04505475 - Oral Surgery in Patients Taking Direct Oral Anticoagulants
Not yet recruiting NCT05997914 - Storytelling for Reducing Gap in Anticoagulation Use in African Americans With Atrial Fibrillation N/A
Recruiting NCT04329390 - MAC Project, Monitoring of AntiCoagulant Therapies (MAC)
Completed NCT03112525 - DAPHNE Study: Direct Anticoagulant PHarmacogeNEtic
Not yet recruiting NCT06452342 - TRanEXamic Acid to Decrease Heavy Menstrual Bleeding in Individuals Anticoagulated for Venous Thromboembolism Pilot Study Phase 4
Recruiting NCT03760874 - Atrial Fibrillation Research Database
Recruiting NCT04046029 - Bivalirudin in Elderly Patients Undergoing Elective Percutaneous Coronary Intervention. Phase 4
Completed NCT04444700 - A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care as a Rapid Response to (SARS-CoV-2) COVID-19 Pandemic Phase 3
Terminated NCT03566303 - Rivaroxaban vs Warfarin in Patients With Metallic Prosthesis Phase 2/Phase 3
Not yet recruiting NCT04128254 - A Prospective Study in Chinese Patients With Lower Extremity Ankle Fracture of Oral Anticoagulants to Prevent Venous Thromboembolism (VTE) Phase 4
Recruiting NCT05946850 - Caudal Analgesia & Anticoagulated Patient
Completed NCT05946863 - Caudal Block & Hip Fracture Surgery in Anticoagulated Patient
Recruiting NCT05545475 - Safety of Anticoagulant Therapy After Tissue Glue for Gastric Varices
Completed NCT06269302 - Comparison of the Effect of Warfarin and Direct Oral Anticoagulants
Active, not recruiting NCT04676880 - Left Atrial Appendage Occlusion for AF Patients Unable to Use Oral Anticoagulation Therapy N/A
Completed NCT05224388 - Evaluating Dose Regimen of Intravenous Unfractionated Heparin and Low Molecular Weight Heparin in Critical Ill Patients Versus Critical Ill COVID-19 Patients Using Anti-Xa Levels.
Completed NCT03871283 - Anticoagulation and Antiplatelet Management During Perioperative Period